

Resource Summary Report

Generated by PRECISE-TBI on Sep 7, 2026

SYFPEITHI: A Database for MHC Ligands and Peptide Motifs

RRID:SCR_013182

Type: Tool

Proper Citation

SYFPEITHI: A Database for MHC Ligands and Peptide Motifs (RRID:SCR_013182)

Resource Information

URL: <http://www.syfpeithi.de/>

Proper Citation: SYFPEITHI: A Database for MHC Ligands and Peptide Motifs (RRID:SCR_013182)

Description: SYFPEITHI is a database comprising more than 7000 peptide sequences known to bind class I and class II MHC molecules. The entries are compiled from published reports only. It contains a collection of MHC class I and class II ligands and peptide motifs of humans and other species, such as apes, cattle, chicken, and mouse, for example, and is continuously updated. Searches for MHC alleles, MHC motifs, natural ligands, T-cell epitopes, source proteins/organisms and references are possible. Hyperlinks to the EMBL and PubMed databases are included. In addition, ligand predictions are available for a number of MHC allelic products. The database is based on previous publications on T-cell epitopes and MHC ligands. It contains information on: - Peptide sequences -anchor positions -MHC specificity -source proteins, source organisms -publication references Since the number of motifs continuously increases, it was necessary to set up a database which facilitates the search for peptides and allows the prediction of T-cell epitopes. The prediction is based on published motifs (pool sequencing, natural ligands) and takes into consideration the amino acids in the anchor and auxiliary anchor positions, as well as other frequent amino acids. The score is calculated according to the following rules: The amino acids of a certain peptide are given a specific value depending on whether they are anchor, auxiliary anchor or preferred residue. Ideal anchors will be given 10 points, unusual anchors 6-8 points, auxiliary anchors 4-6 and preferred residues 1-4 points. Amino acids that are regarded as having a negative effect on the binding ability are given values between -1 and -3. Sponsors: SYFPEITHI is supported by DFG-Sonderforschungsbereich 685 and the European Union: EU BIOMED CT95-1627, BIOTECH CT95-0263, and EU QLQ-CT-1999-00713.

Abbreviations: SYFPEITHI

Synonyms: SYFPEITHI

Resource Type: data or information resource, database

Keywords: epitope, allele, allelic, amino acid, ape, bind, cattle, chicken, class i, class ii, human, immunological database, ligand, mhc, molecule, motif, mouse, natural, organism, peptide, product, protein, sequence, specie, t-cell, bio.tools, FASEB list

Resource Name: SYFPEITHI: A Database for MHC Ligands and Peptide Motifs

Resource ID: SCR_013182

Alternate IDs: nif-0000-21383, biotools:syfpeithi

Alternate URLs: <https://bio.tools/syfpeithi>

Record Creation Time: 20220129T080314+0000

Record Last Update: 20260905T133204+0000

Ratings and Alerts

No rating or validation information has been found for SYFPEITHI: A Database for MHC Ligands and Peptide Motifs.

No alerts have been found for SYFPEITHI: A Database for MHC Ligands and Peptide Motifs.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 269 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Zhang J, et al. (2026) Preparation and Immunogenicity Prediction of Brucella melitensis mRNA Vaccine Candidate Based on omp16 and omp19 Genes. Vaccines, 14(3).

Komatsuda H, et al. (2025) Tumor-promoting function of paternally expressed gene 10 and its immunogenicity in inducing anti-tumor helper T cells in head and neck squamous cell carcinoma. Cancer immunology, immunotherapy : CII, 74(8), 251.

Zhong R, et al. (2025) Identification of new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from LDHC in lung adenocarcinoma. Frontiers in immunology, 16, 1564731.

Sato R, et al. (2025) ROR1 as an Immunotherapeutic Target for Inducing Antitumor Helper T Cell Responses Against Head and Neck Squamous Cell Carcinoma. Cancers, 17(14).

Li Z, et al. (2025) A promising endeavor against human cytomegalovirus: Predominant epitopes-based recombinant subunit vaccine RHEcIE1/pp65/pp150. Virulence, 16(1),

Sattari Sarvari S, et al. (2025) Protective Immunity of a Novel Multi-Epitope Vaccine Encoding OMP31, TF, BLS, SOD, BP26, and L9 Against *Brucella* spp. Infection. Iranian biomedical journal, 29(1 & 2), 36.

Huang R, et al. (2025) Depletion of regulatory T cells enhances the T cell response induced by the neoantigen vaccine with weak immunogenicity. Neoplasia (New York, N.Y.), 59, 101088.

Sanchez-Arsuaga G, et al. (2025) Study of dense granule proteins in *Eimeria* spp. identifies a limited repertoire with potential as vaccine candidates. Frontiers in immunology, 16, 1605984.

Goloudina A, et al. (2025) A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapy. Scientific reports, 15(1), 23171.

Lopez M, et al. (2025) Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption. Breast cancer research : BCR, 27(1), 19.

Wakisaka R, et al. (2024) Hypoxia-Targeted Immunotherapy with PD-1 Blockade in Head and Neck Cancer. Cancers, 16(17).

Zareian N, et al. (2024) A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms. Experimental biology and medicine (Maywood, N.J.), 249, 10021.

Kortleve D, et al. (2024) TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer. Cancer discovery, 14(12), 2450.

Wei Y, et al. (2024) Advances of computational methods enhance the development of multi-epitope vaccines. Briefings in bioinformatics, 26(1).

Jiang Q, et al. (2024) Screening of Bovine Coronavirus Multiepitope Vaccine Candidates: An Immunoinformatics Approach. Transboundary and emerging diseases, 2024, 5986893.

Chieochansin T, et al. (2024) In silico advancements in Peptide-MHC interaction: A molecular dynamics study of predicted glypican-3 peptides and HLA-A*11:01. Heliyon, 10(17), e36654.

Zhang J, et al. (2024) Bioinformatics analysis of the antigenic epitopes of L7/L12 protein in the B- and T-cells active against *Brucella melitensis*. Access microbiology, 6(10).

Jimenez-Cabello L, et al. (2024) Vaccine candidates based on MVA viral vectors expressing VP2 or VP7 confer full protection against Epizootic hemorrhagic disease virus in IFNAR(-/-) mice. Journal of virology, 98(12), e0168724.

Kawakita S, et al. (2024) An integrated database of experimentally validated major histocompatibility complex epitopes for antigen-specific cancer therapy. Antibody therapeutics, 7(2), 177.

Shivarov V, et al. (2024) Differential modulation of mutant CALR and JAK2 V617F-driven oncogenesis by HLA genotype in myeloproliferative neoplasms. *Frontiers in immunology*, 15, 1427810.